• KOL
    • Bipolar Disorder
    • Michael H Allen
    • Michael H Allen: Influence Statistics

      Michael H Allen

      Michael H Allen

      Show email address

      Department of Psychiatry & Behavioral Health, The Ohio State University Wexner Medical Center, Columbus, Ohio. | Helen and Arthur E. Johnson Depression Center, University of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Michael H Allen:Expert Impact

      Concepts for whichMichael H Allenhas direct influence:Bipolar disorder,Suicidal ideation,Suicide risk,Behavioral emergencies,Schizoaffective disorder,Emergency department,Haloperidol promethazine,Emergency psychiatry.

      Michael H Allen:KOL impact

      Concepts related to the work of other authors for whichfor which Michael H Allen has influence:Bipolar disorder,Emergency department,Suicidal ideation,Suicide risk,Mental health,Acute agitation,Inhaled loxapine.

      KOL Resume for Michael H Allen

      Year
      2021

      Department of Psychiatry & Behavioral Health, The Ohio State University Wexner Medical Center, Columbus, Ohio.

      Helen and Arthur E. Johnson Depression Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

      2020

      University of Colorado School of Medicine, Aurora, Colorado

      2019

      Ms. Flynn is with LCF Consulting, LLC in Lake Forest, Illinois. Dr. Allen is with the University of Colorado School of Medicine in Aurora, Colorado.

      RTI International, Research Triangle Park, North Carolina (Dunlap, Orme, Zarkin); Department of Psychiatry and Human Behavior, Brown University and Butler Hospital, Providence, Rhode Island (Arias, Miller); Department of Emergency Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Camargo, Sullivan); Department of Psychiatry, University of Colorado School of Medicine, Aurora (Allen); Division of Epidemiology, Services, and Prevention, National Institute on Drug Abuse, Bethesda, Maryland (Goldstein); Center for Behavioral Health Services, Cape Cod Hospital, Hyannis, Massachusetts (Manton); Department of Quantitative Health Sciences and Department of Family Medicine, University of Massachusetts Medical School, Worcester (Clark); Department of Emergency Medicine, University of Massachusetts Medical School, Worcester (Boudreaux).

      Dr. Daniel is with Bioniche Global Development, LLC in McLean, Virginia and the George Washington University in Washington DC.

      Mr. N. Daniel is with Dartmouth College in Hanover, New Hampshire. Mr. D. Daniel is with Brown University in Providence, Rhode Island.

      2018

      Department of Psychiatry, University of Colorado School of Medicine

      2017

      University of Colorado School of Medicine, Department of Emergency Medicine, Aurora, Colorado

      2016

      Department of Psychiatry, University of Colorado Depression Centre, Aurora, USA

      2015

      University of Colorado Depression Center and Rocky Mountain Crisis Partners, Aurora, Colorado

      2013

      University of Colorado Depression Center, Aurora CO, United States

      Colorado Depression Center, Denver, CO, USA

      2012

      From the Department of Emergency Medicine, Massachusetts General Hospital (SAT, AFS, JAE, CAC), Boston, MA; Butler Hospital (IM), Providence, RI; the Department of Psychiatry, University of Colorado School of Medicine (MHA), Denver, CO; and the Departments of Emergency Medicine, Psychiatry, and Quantitative Health Sciences, University of Massachusetts Medical School (EDB), Worcester, MA.

      Colorado Depression Center, University of Colorado, Aurora, CO

      2011

      University of Colorado Depression Center, Aurora, Colorado

      2009

      Department of Psychiatry, University of Colorado Denver School of Medicine, Denver, CO

      University of Colorado School of Medicine, Denver, USA

      2008

      Denver, Colo.

      2007

      Department of Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado;

      DANIEL: United BioSource Corporation, McLean, VA; CURRIER: University of Rochester Medical Center, Rochester, NY; ZIMBROFF: Pacific Clinical Research Medical Group, Upland, CA; ALLEN: University of Colorado School of Medicine, Denver, CO; OREN and MANOS: Bristol-Myers Squibb Company, Wallingford, CT; MCQUADE: Otsuka America Pharmaceutical, Inc. Princeton, NJ; PIKALOV: Otsuka America Pharmaceutical, Inc., Rockville, MD; CRANDALL: Bristol-Myers Squibb Company, Plainsboro, NJ.

      University of Colorado Health Sciences Center, Denver (M.H.A.)

      2006

      Department of Psychiatry, Clinical Investigation Program, University of Colorado Health Sciences Center. Denver, CO, USA,

      University of Colorado School of Medicine, 4200 East 9th Ave., Box A011-95, Denver, CO 80220, USA.

      2005

      Department of Psychiatry, University of Colorado Health Sciences Center, Denver, CO 80220, USA

      University of Colorado Health Sciences Center;

      2004

      University of Colorado Hospital, Denver, Colorado

      2003

      ALLEN: University of Colorado School of Medicine; CARPENTER: Comprehensive NeuroScience, Inc.; SHEETS: Mental Health Services Design Consultant, Syracuse NY; MICCIO: People, Inc., Poughkeepsie, NY; and ROSS: Ross Editorial.

      2001

      University of Colorado School of Medicine, USA.

      1999

      Michael H. Allen, M.D., is associate director of psychiatry at Denver Health Medical Center

      1995

      Psychiatric Emergency Program at Bellevue Hospital in New York City and clinical assistant professor of psychiatry at New York University School of Medicine

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Michael H Allen is among the top experts in the world.
      Concept World rank
      introduction seci #1
      vb 5 months #1
      nct00628589 #1
      haloperidol promethazine combination #1
      health psychiatric europe #1
      agitation nicotine #1
      excessive sedation haloperidol #1
      nnt haloperidol #1
      humans treatmentresistant depression #1
      doses inhaled loxapine #1
      introduction chemical restraint #1
      acute agitation bpd #1
      structure functions evidence #1
      psychiatry task #1
      emergency voluntary #1
      consecutive agitated #1
      promethazine risk #1
      incidence heisenberg #1
      midazolam respiratory depression #1
      observation process incidence #1
      significance n60 #1
      effective tranquillisation #1
      3month periods study #1
      female psychiatry #1
      lorazepam rescue #1
      seci reduction #1
      respiratory depression lorazepam #1
      evidence haloperidol #1
      task force association #1
      nationally accepted standards #1
      promethazine mix midazolam #1
      haloperidol psychosisinduced aggression #1
      preferred benzodiazepines #1
      emergency departments impact #1
      promethazine psychosisinduced aggression #1
      impact seci #1
      midazolam promethazine #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Michael H Allen

      KOL-Index: 18817

      BACKGROUND: Health services often manage agitated or violent people, and such behaviour is particularly prevalent in emergency psychiatric services (10%). The drugs used in such situations should ensure that the person becomes calm swiftly and safely.

      OBJECTIVES: To examine whether haloperidol plus promethazine is an effective treatment for psychosis-induced aggression.

      SEARCH METHODS: On 6 May 2015 we searched the Cochrane Schizophrenia Group's Register of Trials, which is compiled by ...

      Known for Haloperidol Promethazine | 1 Rct | Psychosis‐induced Aggression | Md 95 | Lorazepam Midazolam
      KOL-Index: 16326

      BACKGROUND: Health services often manage agitated or violent people and for emergency psychiatric services such behaviour is particularly prevalent (10%). The drugs used in this situation should ensure that the person swiftly and safely becomes calm.

      OBJECTIVES: To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression.

      SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group's Register (July 2004).

      SELECTION CRITERIA: We ...

      Known for Haloperidol Promethazine | Psychosis‐induced Aggression | Midazolam N301 | Lorazepam N200 | 2 Rcts
      KOL-Index: 14519

      BACKGROUND: Azapirones are a group of drugs that work at the 5-HT1A receptor and are used to treat patients suffering from generalized anxiety disorder (GAD). However, several studies have shown conflicting results. Whether azapirones are useful as first line treatment in general anxiety disorders still needs to be answered.

      OBJECTIVES: To assess the efficacy and the acceptability of azapirones for the treatment of GAD.

      SEARCH STRATEGY: Initially the Cochrane Collaboration Depression, ...

      Known for Generalized Anxiety Disorder | Treatment Gad | Azapirones Placebo | Anxiety Agents | Randomized Controlled
      KOL-Index: 13978

      BACKGROUND: Health services often manage agitated or violent people, and for emergency psychiatric services such behaviour is particularly prevalent (10%). The drugs used in this situation should ensure that the person swiftly and safely regains composure.

      OBJECTIVES: To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression.

      SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group's Register (January 2008).

      SELECTION ...

      Known for Haloperidol Promethazine | 1 Rct | Psychosis‐induced Aggression | Midazolam Olanzapine | 30 Minutes
      KOL-Index: 12702

      OBJECTIVES: Due to inherent dangers and barriers to research in emergency settings, few data are available to guide clinicians about how best to manage behavioral emergencies. Key constructs such as agitation are poorly defined. This lack of empirical data led us to undertake a survey of expert opinion, results of which were published in the 2001 Expert Consensus Guidelines on the Treatment of Behavioral Emergencies. Several second-generation (atypical) antipsychotics (SGAs) are now ...

      Known for Olanzapine Ziprasidone | Treatment Agitation | Oral Risperidone | Emergency Medical | Expert Consensus
      KOL-Index: 11698

      BACKGROUND: Episodes of depression are the most frequent cause of disability among patients with bipolar disorder. The effectiveness and safety of standard antidepressant agents for depressive episodes associated with bipolar disorder (bipolar depression) have not been well studied. Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania.

      METHODS: In this double-blind, placebo-controlled ...

      Known for Bipolar Depression | Antidepressant Treatment | Mood Stabilizer | Durable Recovery | Depressive Episodes
      KOL-Index: 11558

      OBJECTIVE: This study compared demographic and phenomenological variables between bipolar patients with and without rapid cycling as a function of bipolar I versus bipolar II status.

      METHOD: The authors examined demographic, historical, and symptomatic features of patients with and without rapid cycling in a cross-sectional study of the first 500 patients with bipolar I or bipolar II disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder, a multicenter ...

      Known for Cycling Bipolar | Patients Rapid | Onset Illness | Study Entry | Treatment Enhancement
      KOL-Index: 11363

      BACKGROUND: There is a need for a rapid-acting, non-injection, acute treatment for agitation.

      AIMS: To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia.

      METHOD: This phase III, randomised, double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov number NCT00628589) enrolled 344 individuals who received one, two or three doses of inhaled loxapine (5 or 10 mg) or a placebo. Lorazepam rescue was permitted after dose two. The primary efficacy ...

      Known for Inhaled Loxapine | Acute Treatment | Agitation Schizophrenia | 5 10 | Primary Efficacy Endpoint
      KOL-Index: 10389

      OBJECTIVE: The present study evaluated inhaled loxapine for the acute treatment of agitation in patients with bipolar I disorder.

      METHODS: A Phase 3, randomized, double blind, placebo-controlled, parallel group inpatient study was performed at 17 psychiatric research facilities. Agitated patients (N=314) with bipolar I disorder (manic or mixed episodes) were randomized (1:1:1) to inhaled loxapine 5 mg or 10 mg, or inhaled placebo using the Staccato® system. Following baseline ...

      Known for Acute Treatment | Agitation Patients | Inhaled Loxapine | Clinical Trial | Bipolar Disorder
      KOL-Index: 10110

      Importance: Suicide is a leading cause of deaths in the United States. Although the emergency department (ED) is an opportune setting for initiating suicide prevention efforts, ED-initiated suicide prevention interventions remain underdeveloped.

      Objective: To determine whether an ED-initiated intervention reduces subsequent suicidal behavior.

      Design, Setting, and Participants: This multicenter study of 8 EDs in the United States enrolled adults with a recent suicide attempt or ideation ...

      Known for Suicide Prevention | United States | Emergency Department | Risk Screening | Participants Tau
      KOL-Index: 9830

      OBJECTIVE: Only a few small descriptive studies have examined the prevalence and correlates of tobacco use among bipolar patients. We predicted that poorly controlled manic, depressed and mixed states, and the presence of psychotic symptoms, would be associated with a greater prevalence of smoking among patients with bipolar disorder.

      METHOD: We examined the prevalence of smoking in a cross-sectional sample of 1904 patients with bipolar disorder enrolled in the National Institute of ...

      Known for Bipolar Disorder | Smoking Patients | Prevalence Correlates | Enhancement Program | Systematic Treatment
      KOL-Index: 9164

      OBJECTIVE: The authors conducted a randomized, placebo-controlled study of nicotine replacement therapy for the reduction of agitation and aggression in smokers with schizophrenia.

      METHOD: Participants were 40 smokers 18-65 years of age admitted to a psychiatric emergency service with a diagnosis of schizophrenia confirmed by the Mini International Neuropsychiatric Interview. Patients were screened for agitation with the excited component subscale of the Positive and Negative Syndrome ...

      Known for Nicotine Replacement | Smokers Schizophrenia | Transdermal Patch | Psychiatric Emergency | Service Hospital
      KOL-Index: 8944

      OBJECTIVE: To report efficacy and safety of transitioning patients receiving intramuscular (IM) formulations of aripiprazole or haloperidol to their respective oral formulations.

      METHODS: 448 agitated patients with schizophrenia (73%) or schizoaffective disorder (27%) were randomized to receive aripiprazole IM 9.75 mg, haloperidol IM 6.5 mg, or placebo IM within 24 hours. Patients treated with aripiprazole IM or haloperidol IM who completed this 24-hour IM phase were transitioned to the ...

      Known for Oral Aripiprazole | Acute Treatment | Schizoaffective Disorder | Patients Schizophrenia | 10 Day

      Key People For Bipolar Disorder

      Top KOLs in the world
      #1
      Eduardo Eduard
      bipolar disorder cognitive impairment acute mania
      #2
      Robert M Post
      bipolar disorder affective illness depressed patients
      #3
      Susan L McElroy
      bipolar disorder binge eating bulimia nervosa
      #4
      Paul E Keck
      bipolar disorder acute mania united states
      #5
      Joseph R Calabrese
      bipolar disorder suicidal ideation rapid cycling
      #6
      Gary S Sachs
      bipolar disorder rapid cycling acute mania

      Department of Psychiatry & Behavioral Health, The Ohio State University Wexner Medical Center, Columbus, Ohio. | Helen and Arthur E. Johnson Depression Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado. | University of Colorado

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.